Skip to main content
Year archive

Spexis AG — 2024 filings

All 20 regulatory filings released by Spexis AG (SPEX) in 2024, sourced directly from the official regulator.

20 Filings
2024 Period
2024 filings (20)
Filing Released Lang
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
Delisting Announcement
2024-11-05 English
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
Delisting Announcement
2024-11-05 English
Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.
Legal Proceedings Report
2024-07-29 English
Spexis granted definitive moratorium status until 25 November 2024, subject to monthly progress report obligations, and which can be potentially extended at the request of the administrators.
Legal Proceedings Report
2024-07-29 English
Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Companys moratorium and changes to its Executive Committee.
Legal Proceedings Report
2024-07-22 English
Spexis expects that audit of its 2023 financials will not be completed by 31 July 2024, provides status update relating to the Company’s moratorium and changes to its Executive Committee.
Legal Proceedings Report
2024-07-22 English
Spexis AG: PARI Pharma GmbH announces termination of ColiFin license to EnBiotix, Inc.
Legal Proceedings Report
2024-07-08 English
Spexis AG: PARI Pharma GmbH announces termination of ColiFin® license to EnBiotix, Inc.
Legal Proceedings Report
2024-07-08 English
Spexis launches appeal against SIX Exchange Regulation decision to suspend trading of its shares.
Delisting Announcement
2024-06-04 English
Spexis launches appeal against SIX Exchange Regulation decision to suspend trading of its shares.
Delisting Announcement
2024-06-04 English
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
Report Publication Announcement
2024-05-31 English
Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
Report Publication Announcement
2024-05-31 English
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
Report Publication Announcement
2024-04-30 English
Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
Report Publication Announcement
2024-04-30 English
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Regulatory Filings
2024-04-17 English
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Legal Proceedings Report
2024-04-17 English
Spexis announces closing of sale of preclinical antibiotics program to Basilea
M&A Activity
2024-02-08 English
Spexis announces closing of sale of preclinical antibiotics program to Basilea
M&A Activity
2024-02-08 English
Spexis announces sale of preclinical antibiotics program to Basilea
Regulatory Filings
2024-01-15 English
Spexis announces sale of preclinical antibiotics program to Basilea
Regulatory Filings
2024-01-15 English